Close Menu

NEW YORK — SomaLogic said on Thursday that it has partnered with the US Food and Drug Administration to explore the use of large-scale protein analysis in the development of biosimilar drugs.

Under the terms of the five-year deal, SomaLogic and the FDA's Division of Applied Regulatory Science will use the company's SomaScan proteomics platform to compare changes in circulating proteins following treatment with FDA-approved biologics.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports.

A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.

The New York Times reports Moderna is planning a clinical trial of its SARS-CoV-2 vaccine in children.

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.